H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics (KROS)

August 4, 2026 6:53 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $20.00 price target on Keros Therapeutics (NASDAQ: KROS).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found